Dolby Family Ventures

AI research assistant for biology.

Montara Therapeutics is a biotechnology company focused on developing innovative therapies for central nervous system diseases. It utilizes a precision pharmacology platform that combines human genetics and machine learning to identify and validate drug targets. This approach aims to enhance the safety and effectiveness of treatments for patients suffering from neurological disorders, ultimately improving therapeutic outcomes in this challenging area of healthcare.

Esper Satellite Imagery is focused on developing a constellation of hyperspectral imaging satellites designed to capture detailed imagery across more than 100 spectral bands with a ground sampling distance of 1 meter. The company's modular microsatellites are engineered to provide high-resolution hyperspectral images that can be utilized in various sectors, including agriculture and mining. By measuring minute features of the Earth, these satellites can assess water quality, monitor plant health, and identify underground mineral deposits. Additionally, they facilitate tracking changes in the environment, offering clients crucial data for improving efficiency and addressing challenges related to climate change.

NeuroBionics is a biotechnology company focused on advancing precision bioelectronic medicine through the development of innovative implanted devices. The firm specializes in creating a new class of electronic medicine aimed at revolutionizing neuromodulation. It also designs flexible neuroprostheses that can bidirectionally interface with soft organs, enabling the modulation of their functions. These advancements are intended to treat various diseases and enhance patient outcomes, allowing healthcare providers to better address the needs of their patients.

Calicat is a clean-energy company developing a proprietary electrocatalyst discovery process for electrolyser. The company electrocatalyst discovery is an unprecedented, proprietary, end-to-end ultrahigh throughput AI and data-driven process focused on the discovery of new catalysts for the generation of clean hydrogen and fuel cell power production. The process prepares, characterizes, and quantifies the catalytic activity of millions of compositions per month and then closes the loop with big data analysis and AI to refine/guide the search.

Vandria is a biotechnology company focused on developing mitophagy inducers that promote cellular renewal to combat aging and chronic diseases. These inducers target the elimination and recycling of damaged mitochondria through the autophagy process, which is essential for maintaining healthy mitochondrial function. By enhancing this cellular mechanism, Vandria aims to help patients prevent age-related disorders and improve overall health.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

Montara Therapeutics is a biotechnology company focused on developing innovative therapies for central nervous system diseases. It utilizes a precision pharmacology platform that combines human genetics and machine learning to identify and validate drug targets. This approach aims to enhance the safety and effectiveness of treatments for patients suffering from neurological disorders, ultimately improving therapeutic outcomes in this challenging area of healthcare.

Progentos Therapeutics is focused on developing innovative treatments for multiple sclerosis by harnessing the body's natural repair mechanisms. The company creates novel small-molecule therapeutics aimed at activating oligodendrocyte progenitor cells, which are crucial for myelin regeneration. This approach seeks to help patients recover lost functions and enhance their overall quality of life. Through its targeted research and development efforts, Progentos Therapeutics is dedicated to addressing the challenges associated with chronic diseases, particularly in the context of neurological disorders.

Esper Satellite Imagery is focused on developing a constellation of hyperspectral imaging satellites designed to capture detailed imagery across more than 100 spectral bands with a ground sampling distance of 1 meter. The company's modular microsatellites are engineered to provide high-resolution hyperspectral images that can be utilized in various sectors, including agriculture and mining. By measuring minute features of the Earth, these satellites can assess water quality, monitor plant health, and identify underground mineral deposits. Additionally, they facilitate tracking changes in the environment, offering clients crucial data for improving efficiency and addressing challenges related to climate change.

LeoLabs, Inc. is an aerospace company based in Menlo Park, California, that specializes in phased-array radar technology to provide high-resolution data on objects in low Earth orbit. Founded in 2015, LeoLabs operates a platform for collision avoidance, which automates and modernizes satellite operations while offering foundational mapping data and services to reduce collision risks. Its offerings include rapid orbit determination, early operational support, and ongoing orbit awareness. LeoLabs serves a diverse clientele, including commercial satellite operators, government regulatory bodies, and space agencies, facilitating safe and sustainable operations in space and enhancing visibility for satellite management.

Motif Neurotech develops minimally invasive bioelectronic implants aimed at monitoring and treating severe mental illnesses, particularly treatment-resistant depression. The company focuses on wireless power and data technologies, which facilitate the creation of new, miniature implants designed for tissue stimulation and diagnostic readings. These innovative implants enable patients to repair neural circuits through electronic therapies, offering a promising approach to address complex mental health challenges.

Cognitive Space specializes in developing an artificial intelligence platform aimed at enhancing satellite constellation management. The company's technology enables effective mission management, collections planning, and communication link coordination, helping organizations maximize the revenue and operational capabilities of their satellite networks. By focusing on autonomous asset management, the platform allows commercial satellite operators to optimize capacity in response to evolving demands within a dynamic environment. This innovative approach enhances the organization and orchestration of intelligent machines, ultimately improving the management of Earth's monitoring for various sectors, including economic, environmental, and national security considerations.

Mojo Vision Inc. is a company based in Saratoga, California, established in 2015, that specializes in augmented reality technology. The firm is focused on developing high-performance micro-LED displays for various applications, including consumer, enterprise, and government sectors. It has created the world's smallest and densest dynamic display integrated into a smart contact lens, designed to provide users with timely information without disrupting their focus. This innovative product allows for hands-free connectivity and access to relevant information, thereby minimizing reliance on traditional mobile devices. Additionally, Mojo Vision has formed a joint development agreement with Menicon Co., Ltd. to explore smart contact lens products further, leveraging its advanced micro-LED technology and manufacturing processes to disrupt the display industry.

Sharrow Marine is a subsidiary of Sharrow Engineering, focused on the research and development of high-performance propulsion technologies for both maritime and aeronautical industries. The company specializes in energy-efficient propellers that are custom-designed to enhance the performance of various types of vessels, including commercial marine shipping and recreational boats. Their innovative Sharrow propeller technology is suitable for a wide range of applications, extending beyond propulsion to include industrial and commercial uses. By providing advanced propulsion solutions, Sharrow Marine aims to improve efficiency and performance for its clients across multiple sectors.

Paradromics, Inc. is focused on developing advanced brain-machine interfaces aimed at enhancing communication between the brain and external devices, particularly for individuals with neurodegenerative diseases. The company specializes in creating implantable systems that facilitate neural data decoding, allowing complex brain signals to be translated into data streams suitable for various neural prostheses. Paradromics is dedicated to providing high data-rate brain-computer interface technology that supports bidirectional data transmission, enabling patients to regain functionality lost due to neurological conditions. Founded in 2015, the company is headquartered in Austin, Texas.

Genemod Corporation, based in Seattle, Washington, specializes in developing inventory management software tailored for life scientists. Founded in 2018, the company offers a unified platform that integrates scientific and management tools, allowing researchers to streamline their daily operations in the lab. Its software facilitates the management of laboratory inventory, including consumables, reagents, and equipment, while also supporting project management and scheduling functionalities. By employing data processing algorithms and artificial intelligence, Genemod enhances workflow efficiency, assists in data analysis, and aids in experimental design. The platform is designed to foster collaboration among scientists and improve overall productivity in research environments.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.

Mojo Vision Inc. is a company based in Saratoga, California, established in 2015, that specializes in augmented reality technology. The firm is focused on developing high-performance micro-LED displays for various applications, including consumer, enterprise, and government sectors. It has created the world's smallest and densest dynamic display integrated into a smart contact lens, designed to provide users with timely information without disrupting their focus. This innovative product allows for hands-free connectivity and access to relevant information, thereby minimizing reliance on traditional mobile devices. Additionally, Mojo Vision has formed a joint development agreement with Menicon Co., Ltd. to explore smart contact lens products further, leveraging its advanced micro-LED technology and manufacturing processes to disrupt the display industry.

MooveAI is an automotive company that provides innovative solutions in end-to-end, predictive road intelligence analytics. Their first approach involves continuously collecting trillions of data points about road networks, including data about connected vehicles, road attributes, such as friction and traffic. The data is then integrated into our proprietary location analytics platform, where it is verified and analyzed. Finally, actionable insights are provided in the form of road risk scores that describe the relative safety of millions of individual road segments.

Switch Therapeutics is a biotechnology company established in 2020 and located in San Francisco, California. The company focuses on developing innovative RNA interference (RNAi) therapies aimed at transforming the treatment of various diseases, particularly those affecting the central nervous system and other systemic conditions with significant unmet medical needs. By integrating nucleic acid nanotechnology with RNAi science, Switch Therapeutics creates biomarker-gated genetic medicines designed to activate RNA molecules and therapies specifically in targeted cells. This targeted approach aims to enhance the effectiveness of treatments for central nervous system diseases, providing healthcare providers with advanced therapeutic options.

AccuKnox specializes in cloud security solutions, focusing on a zero-trust approach to safeguard cloud-native organizations. Their platform is designed to protect various container workloads by establishing identity as a perimeter, which helps isolate and secure applications throughout the software development lifecycle. AccuKnox covers a wide range of environments, including public and private clouds, Kubernetes, virtual machines, bare metal, IoT Edge, and 5G security. By employing a differentiated DevSecOps methodology and leveraging an open-source framework, the company enables clients to effectively track and manage tainted data, networking, and system-level restrictions, thereby enhancing the overall security of applications, networks, and data.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

Authentic Vision GmbH specializes in anti-counterfeiting and authentication technologies aimed at safeguarding organizations' investments in product innovation and brand reputation. Founded in 2012 and headquartered in Salzburg, Austria, with an office in Saratoga, California, the company offers a patented Unique Label technology that combines QR code functionality with the security features of holograms. Its CheckifReal application provides visual recognition capabilities, allowing users to easily distinguish between authentic labels and counterfeit versions. Additionally, Authentic Vision's services include customer communication, client label management, business intelligence, and information collection. The company collaborates with universities and leading security printing firms to stay at the forefront of brand protection and consumer engagement solutions.

Atomos Space is an aerospace company founded in 2018 and located in Denver, Colorado. It specializes in the development of orbital transfer vehicles and space nuclear technology. The company's vehicles are designed to enhance maneuverability and create a sustainable orbital environment, which allows satellite operators to significantly lower their costs for reaching their intended destinations in space. By making various orbits more accessible, Atomos aims to improve the efficiency and effectiveness of satellite deployment and operations.

Cajal Neuroscience is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. By integrating human genetics, functional genomics, and advanced microscopy, the company aims to identify novel therapeutic targets. Cajal utilizes a range of cutting-edge technologies, including high-throughput functional genomics and multi-omics approaches, to screen for targets that significantly influence the progression of neurodegenerative diseases. This comprehensive methodology supports the development of precision medicine, ultimately aiding healthcare professionals in treating patients affected by these conditions.

MedCrypt Inc. is a cybersecurity company specializing in the protection of medical devices. Founded in 2016 and based in Encinitas, California, MedCrypt provides data security solutions for a wide range of medical devices, including implantable devices like pacemakers and various surgical robots. The company's platform offers data security as a service to medical device original equipment manufacturers (OEMs), enabling them to implement essential security features quickly and efficiently. These features include user authentication, data encryption, and transaction monitoring to detect potential malicious behavior. By integrating security capabilities into medical devices with minimal code, MedCrypt allows engineers to focus on developing innovative clinical functionalities while ensuring the safety and integrity of device operations.

Canaery is focused on developing a neural interface that digitizes the sense of smell to analyze the scent fingerprints of objects. This innovative technology is designed to identify hazardous compounds at critical locations such as ports and inspection points. By utilizing this neurotech device, clients can detect not only the presence of dangerous substances but also gain insights into the nature and condition of the objects being inspected.

OKAPI:Orbits is a software-as-a-service startup focused on enhancing the sustainability of space travel through advanced collision avoidance solutions for satellites. The company provides a comprehensive platform that includes features such as environmental visualization, maneuver design, conjunction analysis, re-entry predictions, and high-accuracy orbit propagation. These tools enable researchers and satellite operators to effectively monitor risks and ensure secure operations in space, contributing to a more sustainable environment in orbit. By facilitating seamless integration with ground segments, OKAPI:Orbits aims to support the growing demands of space exploration while prioritizing safety and sustainability.

Ubotica specializes in deploying advanced artificial intelligence technologies aboard satellites to provide real-time insights from space-based systems. The company develops semi-autonomous satellite systems that leverage technical expertise in computer vision and machine learning. By focusing on embedded systems, Ubotica serves various market segments, including space, Internet of Things (IoT), industry, and biomedical sectors. This approach enables clients to maximize the utility and output of their satellite systems, enhancing data accessibility and operational efficiency.

DigiLens Inc. is a developer and manufacturer of optical platform and photopolymer technology solutions specializing in waveguide displays for extended reality (XR) applications. The company offers a range of products, including the Crystal30 and Crystal50 lenses, which enable original equipment manufacturers (OEMs) to create customizable XR devices for both enterprise and consumer markets. DigiLens also provides innovative solutions like the DigiLens AutoHUD, which enhances the field of view and reduces component size in heads-up displays, and CrystalClear, an augmented reality heads-up display. In addition to display technologies, DigiLens supplies light engines and hardware development kits, such as Insight30, which assist users in evaluating and developing wearable devices. Founded in 1997 and based in Sunnyvale, California, DigiLens has positioned itself as a leader in holographic waveguide technology, enabling various industries, including automotive, enterprise, consumer, avionics, and military, to leverage XR capabilities.

Diamond Age is focused on automating the home construction process to address labor shortages within the production housing industry. The company employs a Robotics-as-a-Service model that integrates 3D printing, mechatronics, and robotics, significantly reducing construction times from nine months to just thirty days. By developing advanced robotic tools, Diamond Age aims to minimize the manual labor needed in home building. Additionally, the company collaborates directly with landholders to streamline the supply chain, facilitating more affordable housing options for home buyers. Through these innovative approaches, Diamond Age seeks to unlock substantial growth potential in the housing market.

Mojo Vision Inc. is a company based in Saratoga, California, established in 2015, that specializes in augmented reality technology. The firm is focused on developing high-performance micro-LED displays for various applications, including consumer, enterprise, and government sectors. It has created the world's smallest and densest dynamic display integrated into a smart contact lens, designed to provide users with timely information without disrupting their focus. This innovative product allows for hands-free connectivity and access to relevant information, thereby minimizing reliance on traditional mobile devices. Additionally, Mojo Vision has formed a joint development agreement with Menicon Co., Ltd. to explore smart contact lens products further, leveraging its advanced micro-LED technology and manufacturing processes to disrupt the display industry.

MindImmune Therapeutics, Inc. is a pharmaceutical company focused on developing innovative drugs that target the immune system to address diseases of the central nervous system, including Alzheimer’s and Huntington’s diseases, as well as pain and psychiatric disorders. Recognizing the critical role of immune system dysfunction in brain health, MindImmune aims to leverage this connection to create effective therapeutic options. Founded in 2016 and headquartered in Kingston, Rhode Island, the company is establishing partnerships with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to enhance its research and development efforts. MindImmune is committed to advancing its drug development programs within the growing Rhode Island academic neuroscience ecosystem.

Ursa Major Technologies, Inc., established in 2015 and based in Berthoud, Colorado, specializes in manufacturing propulsion solutions tailored for the microsatellite and nanosatellite launch market. The company's product portfolio includes the Ursa Major Hadley and Ripley engines, which are predominantly (over 80%) additively manufactured using innovative, in-house developed materials and processes. These engines, running on liquid oxygen and kerosene, are designed to provide superior performance, reliability, and cost-effectiveness for aerospace clients.

Sepion Technologies is an advanced membrane company based in Emeryville, California, founded in 2015. The company specializes in developing a suite of highly-tunable nanoscale membranes for various industrial applications, particularly in the energy storage sector. Sepion focuses on manufacturing innovative products, including lithium-metal batteries, by integrating nanoscience, polymer chemistry, and cell engineering. Its proprietary composite membrane serves as a cost-effective alternative to traditional ceramic separators used in lithium batteries, offering improved performance and the capability to be produced in large-area formats. This innovation enables battery manufacturers to enhance energy density in their products, thereby advancing the overall efficiency of energy storage solutions.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.

DigiLens Inc. is a developer and manufacturer of optical platform and photopolymer technology solutions specializing in waveguide displays for extended reality (XR) applications. The company offers a range of products, including the Crystal30 and Crystal50 lenses, which enable original equipment manufacturers (OEMs) to create customizable XR devices for both enterprise and consumer markets. DigiLens also provides innovative solutions like the DigiLens AutoHUD, which enhances the field of view and reduces component size in heads-up displays, and CrystalClear, an augmented reality heads-up display. In addition to display technologies, DigiLens supplies light engines and hardware development kits, such as Insight30, which assist users in evaluating and developing wearable devices. Founded in 1997 and based in Sunnyvale, California, DigiLens has positioned itself as a leader in holographic waveguide technology, enabling various industries, including automotive, enterprise, consumer, avionics, and military, to leverage XR capabilities.

TripleBlind, Inc. is a Kansas City-based company incorporated in 2019 that provides an online platform enabling organizations to collaborate while safeguarding sensitive data and algorithms. The company specializes in privacy-enhancing computation, offering a software-only solution delivered through a simple API. TripleBlind focuses on sectors such as healthcare and financial services, utilizing innovations like federated learning and multi-party computation to enhance the scalability and efficiency of privacy-preserving technology. Its platform allows institutions to share and monetize regulated data without compromising privacy, ensuring compliance with regulations like HIPAA and GDPR. By facilitating collaboration around sensitive data without decryption, TripleBlind enables clients to generate new revenue, derive deeper insights, and improve modeling and analysis. The company is supported by notable investors including Accenture, General Catalyst, and The Mayo Clinic, and it integrates seamlessly with major cloud platforms.

Calicat is a clean-energy company developing a proprietary electrocatalyst discovery process for electrolyser. The company electrocatalyst discovery is an unprecedented, proprietary, end-to-end ultrahigh throughput AI and data-driven process focused on the discovery of new catalysts for the generation of clean hydrogen and fuel cell power production. The process prepares, characterizes, and quantifies the catalytic activity of millions of compositions per month and then closes the loop with big data analysis and AI to refine/guide the search.

Acrigen Biosciences focuses on enhancing the safety and efficacy of gene editing technologies, particularly those based on the CRISPR-Cas system. Founded in 2019 and headquartered in Berkeley, California, the company develops innovative solutions that aim to produce effective in vivo drug therapies to combat various diseases. Acrigen's proprietary technologies include Acro proteins that regulate the CRISPR-Cas gene editing process and an advanced bioinformatics discovery software platform that identifies suitable CRISPR systems for human therapeutic applications. Through these advancements, Acrigen Biosciences seeks to improve the precision, efficacy, and safety of genetic therapies, ultimately contributing to the potential prevention and cure of debilitating diseases.

Diamond Age is focused on automating the home construction process to address labor shortages within the production housing industry. The company employs a Robotics-as-a-Service model that integrates 3D printing, mechatronics, and robotics, significantly reducing construction times from nine months to just thirty days. By developing advanced robotic tools, Diamond Age aims to minimize the manual labor needed in home building. Additionally, the company collaborates directly with landholders to streamline the supply chain, facilitating more affordable housing options for home buyers. Through these innovative approaches, Diamond Age seeks to unlock substantial growth potential in the housing market.

Paradromics, Inc. is focused on developing advanced brain-machine interfaces aimed at enhancing communication between the brain and external devices, particularly for individuals with neurodegenerative diseases. The company specializes in creating implantable systems that facilitate neural data decoding, allowing complex brain signals to be translated into data streams suitable for various neural prostheses. Paradromics is dedicated to providing high data-rate brain-computer interface technology that supports bidirectional data transmission, enabling patients to regain functionality lost due to neurological conditions. Founded in 2015, the company is headquartered in Austin, Texas.

Strateos specializes in automating chemistry, biology, and tissue analysis in closed-loop robotic labs, accelerating drug discovery programs for pharmaceutical partners. By combining advanced robotics, software for imaging and analytics, and remote cloud laboratories, Strateos enables more rapid and efficient discovery of new drug candidates. The company was formed through a merger of Transcriptic, which developed the first robotic cloud laboratory platform for life science research, and 3Scan, which specialized in automating tissue analysis. Strateos aims to express life science methods as data, enabling infrastructure virtualization and driving the next generation of discovery with significant time and cost efficiencies.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.

TripleBlind, Inc. is a Kansas City-based company incorporated in 2019 that provides an online platform enabling organizations to collaborate while safeguarding sensitive data and algorithms. The company specializes in privacy-enhancing computation, offering a software-only solution delivered through a simple API. TripleBlind focuses on sectors such as healthcare and financial services, utilizing innovations like federated learning and multi-party computation to enhance the scalability and efficiency of privacy-preserving technology. Its platform allows institutions to share and monetize regulated data without compromising privacy, ensuring compliance with regulations like HIPAA and GDPR. By facilitating collaboration around sensitive data without decryption, TripleBlind enables clients to generate new revenue, derive deeper insights, and improve modeling and analysis. The company is supported by notable investors including Accenture, General Catalyst, and The Mayo Clinic, and it integrates seamlessly with major cloud platforms.

Roviero is an AI startup focused on developing advanced graph processors for edge computing applications. The company has created the CortiOne Neural Processing Engine and the CortiSoft compiler technology, which work together to deliver high performance with minimal power consumption and latency on edge devices. Their Native Graph AI Processor enables native intelligence in a variety of devices, including cameras, IoT devices, mobile phones, and computers. Unlike traditional edge AI processors, Roviero's technology offers significant performance and power optimization while simplifying programming for product designers. This innovation aims to democratize AI computing, paving the way for a new generation of intelligent edge devices.

CytoVale, Inc. is a medical technology company based in San Francisco, California, established in 2012. The company specializes in developing biomarkers that leverage the mechanical properties of individual cells, a field known as mechanomics. By utilizing microfluidics technology, CytoVale can efficiently route and physically probe single cells to measure multiple biomarkers simultaneously. This innovative approach aims to enhance early detection of immune-mediated diseases, particularly sepsis, thereby improving patient outcomes and reducing treatment costs. CytoVale's integration of cell mechanics with machine learning positions it at the forefront of revolutionizing diagnostic practices in healthcare.

Sea Machines Robotics, Inc. is an autonomous technology company based in Boston, Massachusetts, specializing in the development and manufacturing of autonomous control and navigation systems for the commercial marine and boating industries. Founded in 2014, the company creates advanced control systems designed to improve operational safety and efficiency for various marine applications. Its product lineup includes the SM300, which allows for remote command of vessels; the SM200, facilitating integrated control for collaborative operations; and the SM400, an AI-powered situational awareness system tailored for container ships. Additionally, the company offers the RC NXT, a remote command system for existing and new marine vessels, and the DP-NXT, which enables traditional vessels to operate with minimal or no crew onboard. Sea Machines Robotics also provides solutions for unmanned applications, including bathymetric survey vessels and subsea asset inspections, focusing on sectors such as shipping, offshore energy, and maritime logistics.

Authentic Vision GmbH specializes in anti-counterfeiting and authentication technologies aimed at safeguarding organizations' investments in product innovation and brand reputation. Founded in 2012 and headquartered in Salzburg, Austria, with an office in Saratoga, California, the company offers a patented Unique Label technology that combines QR code functionality with the security features of holograms. Its CheckifReal application provides visual recognition capabilities, allowing users to easily distinguish between authentic labels and counterfeit versions. Additionally, Authentic Vision's services include customer communication, client label management, business intelligence, and information collection. The company collaborates with universities and leading security printing firms to stay at the forefront of brand protection and consumer engagement solutions.

Libra Therapeutics, Inc. is a biotechnology company based in San Diego, California, founded in 2019. The company is dedicated to developing innovative disease-modifying therapeutics aimed at restoring cellular balance in patients suffering from neurodegenerative diseases such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. Libra Therapeutics focuses on small molecule drugs that enhance autophagy, allowing for the rapid clearance of toxic proteins and the reduction of neurotoxic protein production. Through its distinct molecular approaches, the company aims to address the cellular imbalances that characterize these debilitating conditions, thereby providing potential new treatment options for affected individuals.

Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.

NeuroTherpia, Inc., established in 2015 by Drs. Mohamed Naguib and Joseph Foss, is focused on creating innovative therapies for diseases characterized by neuroinflammation. The company's primary compound, NTRX-07, has demonstrated the ability to reduce the activation of microglial cells in the brain, which in turn diminishes inflammation and subsequent injury to nearby nerve cells. This reduction in inflammation has potential applications in treating and preventing neuropathic pain associated with nerve injuries and chemotherapy, as well as in reversing effects related to Alzheimer's disease. Currently, NeuroTherpia is conducting preclinical safety studies and plans to initiate human trials for NTRX-07.

NativeWaves is focused on enhancing the event viewing experience for audiences worldwide through its innovative audio synchronization and streaming technology. The company collaborates with partners to curate engaging content from live events and develops tools that facilitate personalized viewing experiences. By offering efficient and versatile content delivery solutions, NativeWaves allows for seamless integration into existing workflows without requiring major changes. Its software enables the translation of movies, sports events, and videos into multiple languages while eliminating issues such as buffering and synchronization delays. Additionally, users benefit from real-time access to live statistics and insights on alternate screens, allowing them to enjoy their favorite entertainment in a manner tailored to their preferences.

Atomwise, Inc. is a biotechnology company based in San Francisco that specializes in using deep learning artificial intelligence for small molecule drug discovery. Founded in 2012, Atomwise developed the AtomNet platform, which enables virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical approach that leverages experimental affinity measurements and protein structures. The company focuses on addressing over 600 unique disease targets and has established partnerships with more than 250 organizations, including pharmaceutical and biotechnology firms. Atomwise's technology has been recognized for its ability to unlock previously undruggable targets, and the company has raised significant funding to support its mission of accelerating drug discovery and development.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

Atmosic Technologies, Inc., established in 2016 and headquartered in Campbell, California, is a fabless semiconductor company specializing in ultra-low power wireless technologies. Its core business is designing innovative solutions that significantly reduce or eliminate battery dependency in Internet of Things (IoT) devices. Atmosic's products, including the ATM2, ATM3, ATM33, and ATM34 series, enable IoT devices to harvest energy from ambient sources like light, radio frequency, thermal, and kinetic, thereby extending battery life or making devices battery-free. This innovation benefits various IoT applications across personal, home, auto, healthcare, industrial, enterprise, and smart cities segments, reducing costs and maintenance efforts for designers, manufacturers, developers, and end users.

GenomSys SA, established in 2016 and headquartered in Lausanne, Switzerland, specializes in developing tools and applications for processing and sharing DNA data. The company's core offering is a modular, robust, and certified platform that efficiently processes, stores, and shares genomic data. This platform, based on the ISO/IEC 23092 genomic standard, enables secure storage of individual DNA data on personal devices and facilitates sharing with practitioners for various applications, including diagnostics, pharmacogenomics, personalized treatments, and dietary recommendations. GenomSys' solutions are designed to be cheaper, faster, interoperable, and regulatory-conscious, accelerating the widespread adoption of personalized genomics.

Strateos specializes in automating chemistry, biology, and tissue analysis in closed-loop robotic labs, accelerating drug discovery programs for pharmaceutical partners. By combining advanced robotics, software for imaging and analytics, and remote cloud laboratories, Strateos enables more rapid and efficient discovery of new drug candidates. The company was formed through a merger of Transcriptic, which developed the first robotic cloud laboratory platform for life science research, and 3Scan, which specialized in automating tissue analysis. Strateos aims to express life science methods as data, enabling infrastructure virtualization and driving the next generation of discovery with significant time and cost efficiencies.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.

Lightform, Inc. is a computer vision and hardware company based in San Francisco, California, specializing in projected augmented reality. Founded in 2014, the company develops innovative solutions that enable users to create and project animated content onto various scenes. Their offerings include sound-reactive projectors, projector kits, and a desktop application that simplifies the projection mapping workflow, allowing for seamless control and content updates via laptop or smartphone. Lightform's technology incorporates 3D scanning capabilities, enabling the capture of complex scenes and automatic alignment adjustments, which enhance the integration of real objects with projected imagery. By streamlining the creation and projection process, Lightform empowers users to transform spaces with dynamic visual effects and ambient interfaces.

NativeWaves is focused on enhancing the event viewing experience for audiences worldwide through its innovative audio synchronization and streaming technology. The company collaborates with partners to curate engaging content from live events and develops tools that facilitate personalized viewing experiences. By offering efficient and versatile content delivery solutions, NativeWaves allows for seamless integration into existing workflows without requiring major changes. Its software enables the translation of movies, sports events, and videos into multiple languages while eliminating issues such as buffering and synchronization delays. Additionally, users benefit from real-time access to live statistics and insights on alternate screens, allowing them to enjoy their favorite entertainment in a manner tailored to their preferences.

Kuprion Inc. is a manufacturer and licensor of nano copper inks and pastes, primarily used in printable electronics and integrated circuit chips. Founded in 2016 and based in Palo Alto, California, the company specializes in its NSA-16 nano copper solder adhesive, which is designed for applications across various sectors, including aerospace, automotive, consumer electronics, and healthcare. Kuprion's technology, which emerged from research at Lockheed Martin, offers superior electrical and thermal conductivity compared to traditional solder, making it suitable for high-performance and high-reliability applications in smaller and more powerful electronic devices. The company also provides assembly, packaging, and consulting services, and has secured numerous patents and significant interest from major commercial clients. With manufacturing capabilities in San Jose, California, Kuprion aims to revolutionize the market for advanced electronics by offering a reliable, RoHS-compliant alternative to conventional materials.

Phylagen, Inc. is a data analytics company based in San Francisco that specializes in microbiome data analytics. Founded in 2014, the company employs DNA sequencing and machine learning to analyze complex genetic signatures within the environmental microbiome, transforming this extensive dataset into actionable insights for various industries. Phylagen also develops automated biosensors for indoor microbiome monitoring, which aim to enhance human health and safety by enabling early detection of pathogens, including COVID-19. Additionally, the company's solutions help manage allergy and asthma triggers, ensuring a healthier indoor environment for users.

Ultraleap Limited is a leading developer of mid-air haptic control systems and 3D hand tracking technology. Formerly known as Ultrahaptics, the company specializes in creating solutions that utilize ultrasound to generate tactile sensations, enabling users to feel three-dimensional shapes and textures without physical contact. Its flagship products include the Leap Motion Controller, which captures hand movements, and the VR Developer Mount, designed for enhancing virtual reality experiences on various headsets. The company's innovative technology is applicable across multiple industries such as extended reality, automotive, digital signage, industrial automation, consumer electronics, and location-based entertainment. Established in 2013 and headquartered in Bristol, United Kingdom, Ultraleap also has a subsidiary in Silicon Valley, United States.

Mojo Vision Inc. is a company based in Saratoga, California, established in 2015, that specializes in augmented reality technology. The firm is focused on developing high-performance micro-LED displays for various applications, including consumer, enterprise, and government sectors. It has created the world's smallest and densest dynamic display integrated into a smart contact lens, designed to provide users with timely information without disrupting their focus. This innovative product allows for hands-free connectivity and access to relevant information, thereby minimizing reliance on traditional mobile devices. Additionally, Mojo Vision has formed a joint development agreement with Menicon Co., Ltd. to explore smart contact lens products further, leveraging its advanced micro-LED technology and manufacturing processes to disrupt the display industry.

System1 Biosciences, Inc., founded in 2017 and headquartered in San Francisco, California, is a neurotherapeutics company focused on drug discovery for complex neurological and psychiatric diseases such as epilepsy, autism, and schizophrenia. By utilizing phenotypic screening, the company aims to overcome the limitations of existing discovery techniques in these challenging areas. System1 integrates cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics to achieve detailed characterizations of diseases, referred to as "deep phenotypes." These insights are employed to identify novel therapeutic targets and develop effective drug treatments.

Vium, Inc. is a biotechnology company focused on transforming preclinical research and enhancing animal welfare through the development of digital biomarkers. Fully accredited by AAALAC International, Vium has received commendation for its commitment to the principles of humane animal research. The company's platform, known as Digital Vivarium and Vium Cloud, integrates advanced technologies such as computer vision, artificial intelligence, and machine learning to non-invasively capture and analyze physiological metrics and behaviors. This innovative approach provides researchers across biotechnology, pharmaceutical, and academic sectors with accurate data that facilitates better decision-making regarding which compounds to advance to clinical trials. Founded in 2013 and headquartered in San Mateo, California, Vium aims to accelerate the preclinical drug discovery and development pipeline while ensuring ethical standards in research practices.

Paradromics, Inc. is focused on developing advanced brain-machine interfaces aimed at enhancing communication between the brain and external devices, particularly for individuals with neurodegenerative diseases. The company specializes in creating implantable systems that facilitate neural data decoding, allowing complex brain signals to be translated into data streams suitable for various neural prostheses. Paradromics is dedicated to providing high data-rate brain-computer interface technology that supports bidirectional data transmission, enabling patients to regain functionality lost due to neurological conditions. Founded in 2015, the company is headquartered in Austin, Texas.

Zebra Medical Vision Ltd. is a company that develops an imaging analytics platform aimed at enhancing patient care in healthcare institutions. Founded in 2014 and based in Shefayim, Israel, the platform utilizes advanced learning and computer vision algorithms to assist clinicians in identifying patients at risk of various diseases. This technology supports healthcare providers in implementing effective risk management and preventative care strategies. Zebra Medical Vision also supplies tools and datasets for machine-learning researchers, facilitating the rapid development of decision support tools and diagnostic solutions. The company has established strategic partnerships with organizations such as USARAD Holdings and TELUS Ventures, and has secured a total of $52 million in funding from notable investors, including Khosla Ventures and Nvidia. Its AI-driven products are FDA cleared and are utilized in hospitals across multiple regions, including the U.S., Europe, Australia, India, and Latin America, positioning Zebra Medical Vision as a leader in the field of medical imaging and analytics.

Quince Therapeutics is a preclinical stage biopharmaceutical company dedicated to developing innovative precision therapeutics for debilitating and rare diseases. The company has created a unique bone-targeting drug platform that enables the precise delivery of small molecules, peptides, or large molecules directly to the site of bone fractures and diseases. This targeted approach aims to enhance healing rates while minimizing off-target safety concerns often associated with non-targeted therapies. Quince Therapeutics focuses on addressing impairments related to strength, functionality, debilitating pain, and other serious health challenges.

Phase Four LLC is a manufacturer of satellite propulsion systems based in Pasadena, California, founded in 2015. The company specializes in electric propulsion for small satellites, offering innovative products such as the CubeSats ambipolar thruster and the Maxwell plasma propulsion solution. Its core technology, the Radio Frequency Thruster (RFT), distinguishes itself by eliminating the need for a hollow cathode and high voltage electronics, resulting in significant cost savings, reduced size of power electronics, and compatibility with various propellants. Phase Four's propulsion systems are designed to be small and lightweight, featuring a patented magnetic nozzle to optimize thrust, allowing clients to effectively maneuver satellites into various orbits while minimizing operational costs. The company's products are utilized across commercial, civil, and scientific space missions, reflecting its commitment to advancing the capabilities of space exploration.

Atomwise, Inc. is a biotechnology company based in San Francisco that specializes in using deep learning artificial intelligence for small molecule drug discovery. Founded in 2012, Atomwise developed the AtomNet platform, which enables virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical approach that leverages experimental affinity measurements and protein structures. The company focuses on addressing over 600 unique disease targets and has established partnerships with more than 250 organizations, including pharmaceutical and biotechnology firms. Atomwise's technology has been recognized for its ability to unlock previously undruggable targets, and the company has raised significant funding to support its mission of accelerating drug discovery and development.

Envisagenics, Inc. is a biotechnology company founded in 2013 and headquartered in Huntington, New York. It specializes in the development of a predictive analytics platform aimed at accelerating the discovery of RNA therapeutics. The company leverages advanced artificial intelligence and machine learning algorithms to analyze transcriptomic data, helping researchers identify and validate potential drug targets. Envisagenics' flagship technology, SpliceCore, is a cloud-based platform that utilizes RNA splicing analytics to predict drug targets and biomarkers, addressing the complexities of biomedical data. Given that over 30 million people in the U.S. suffer from genetic diseases or cancers related to RNA splicing errors, the company's mission is to streamline the development of innovative therapeutic solutions. By providing an in-silico RNA therapeutics discovery platform, Envisagenics enhances the efficiency of drug development processes, reducing time, cost, and risk associated with bringing new therapies to market through partnerships with biopharmaceutical companies.

Ursa Major Technologies, Inc., established in 2015 and based in Berthoud, Colorado, specializes in manufacturing propulsion solutions tailored for the microsatellite and nanosatellite launch market. The company's product portfolio includes the Ursa Major Hadley and Ripley engines, which are predominantly (over 80%) additively manufactured using innovative, in-house developed materials and processes. These engines, running on liquid oxygen and kerosene, are designed to provide superior performance, reliability, and cost-effectiveness for aerospace clients.

Lightform, Inc. is a computer vision and hardware company based in San Francisco, California, specializing in projected augmented reality. Founded in 2014, the company develops innovative solutions that enable users to create and project animated content onto various scenes. Their offerings include sound-reactive projectors, projector kits, and a desktop application that simplifies the projection mapping workflow, allowing for seamless control and content updates via laptop or smartphone. Lightform's technology incorporates 3D scanning capabilities, enabling the capture of complex scenes and automatic alignment adjustments, which enhance the integration of real objects with projected imagery. By streamlining the creation and projection process, Lightform empowers users to transform spaces with dynamic visual effects and ambient interfaces.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and addressing neurodegenerative diseases. The company's lead candidate, ATH-1017, is a small hepatocyte growth factor/MET activator designed to penetrate the blood-brain barrier and is currently undergoing various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. Additionally, Athira is advancing other candidates, including ATH-1019, which is in preclinical development for depression, and ATH-1018, aimed at treating peripheral neuropathy. Founded in 2011 and originally named M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its commitment to innovative therapies that positively impact individuals affected by brain disorders.

Stellar Labs, Inc., incorporated in 2014 and based in Burlingame, California, operates within the technology sector, focusing on the private aviation industry. The company has developed an advanced commercial operations system that integrates an all-digital distribution network, aiming to transform and enhance business aviation. Stellar Labs offers a suite of cloud-based applications designed to cater to a range of operational needs, from simple single-aircraft management to complex operations involving large fleets and multiple bases. This innovative approach positions Stellar Labs as a key player in revolutionizing the efficiency and effectiveness of private aviation services.

Chirp Microsystems, Inc. is a company founded in 2013 and based in Berkeley, California, specializing in the design, development, and manufacturing of low power ultrasonic three-dimensional sensing solutions. The company's innovative technology provides millimeter-accurate range information and utilizes machine learning and neural network algorithms to enhance performance in various applications. Chirp's ultrasonic 3D-sensing systems are particularly advantageous for consumer electronics, smart home devices, and industrial automation, outperforming traditional infrared-based alternatives. This technology enables continuous sensing capabilities, allowing smart-home devices to remain operational even on battery power, thus facilitating wake-on-approach functionalities.

Mixed Dimensions Inc. is a software development company based in San Francisco, California, that specializes in the three-dimensional (3D) printing industry. Founded in 2009, the company offers several innovative solutions, including Makeprintable, a cloud-based service that optimizes 3D CAD files by fixing errors to ensure they are suitable for printing. It also provides 3D Collectible, which integrates a printing technology platform with existing 3D printers to produce customizable printed objects. Additionally, Mixed Dimensions has developed Gameprint, a platform designed to capture and share gameplay moments in a 3D environment. The company's focus on bridging the digital and physical worlds enhances user experiences in game development and 3D printing, allowing for the on-demand creation of unique, one-of-a-kind products.

Alzeca Biosciences, Inc. is focused on developing advanced MRI-based imaging agents aimed at the early diagnosis of Alzheimer’s disease and other neurodegenerative disorders. Founded in 2011 and headquartered in Houston, Texas, the company is working on its primary product, the ADx nanoparticle, which serves as a magnetic resonance imaging contrast agent targeting amyloid plaques associated with Alzheimer's. This innovative approach allows for the detection of abnormal proteins that accumulate in the brain long before cognitive symptoms manifest, potentially facilitating earlier intervention. With Alzheimer's affecting millions of individuals worldwide and associated healthcare costs projected to soar, Alzeca's efforts are aligned with the urgent need for more effective diagnostic methods in the fight against neurodegenerative diseases.

Tempo Automation Holdings, established in 2013 and headquartered in San Francisco, specializes in manufacturing low-volume electronics products. The company's core business involves designing and assembling printed circuit boards (PCBs) using a proprietary, software-automated platform. This platform enables Tempo to provide its customers, predominantly from industries such as aerospace, medical technology, and automotive, with unparalleled speed, quality, and transparency during the critical prototype and new product introduction stages. By optimizing the complex PCB manufacturing process, Tempo Automation empowers its clients to iterate quickly and bring innovative products to market more efficiently.

Ultraleap Limited is a leading developer of mid-air haptic control systems and 3D hand tracking technology. Formerly known as Ultrahaptics, the company specializes in creating solutions that utilize ultrasound to generate tactile sensations, enabling users to feel three-dimensional shapes and textures without physical contact. Its flagship products include the Leap Motion Controller, which captures hand movements, and the VR Developer Mount, designed for enhancing virtual reality experiences on various headsets. The company's innovative technology is applicable across multiple industries such as extended reality, automotive, digital signage, industrial automation, consumer electronics, and location-based entertainment. Established in 2013 and headquartered in Bristol, United Kingdom, Ultraleap also has a subsidiary in Silicon Valley, United States.

Quince Therapeutics is a preclinical stage biopharmaceutical company dedicated to developing innovative precision therapeutics for debilitating and rare diseases. The company has created a unique bone-targeting drug platform that enables the precise delivery of small molecules, peptides, or large molecules directly to the site of bone fractures and diseases. This targeted approach aims to enhance healing rates while minimizing off-target safety concerns often associated with non-targeted therapies. Quince Therapeutics focuses on addressing impairments related to strength, functionality, debilitating pain, and other serious health challenges.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and addressing neurodegenerative diseases. The company's lead candidate, ATH-1017, is a small hepatocyte growth factor/MET activator designed to penetrate the blood-brain barrier and is currently undergoing various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. Additionally, Athira is advancing other candidates, including ATH-1019, which is in preclinical development for depression, and ATH-1018, aimed at treating peripheral neuropathy. Founded in 2011 and originally named M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its commitment to innovative therapies that positively impact individuals affected by brain disorders.

Echo is a provider of am automated microscope intended for biological research and pathologies. The company's product provides features like inverted images, cell counting, phase contrast, brightfield and fluorescence, enabling customers to have accurate images at a lower cost.

DigiLens Inc. is a developer and manufacturer of optical platform and photopolymer technology solutions specializing in waveguide displays for extended reality (XR) applications. The company offers a range of products, including the Crystal30 and Crystal50 lenses, which enable original equipment manufacturers (OEMs) to create customizable XR devices for both enterprise and consumer markets. DigiLens also provides innovative solutions like the DigiLens AutoHUD, which enhances the field of view and reduces component size in heads-up displays, and CrystalClear, an augmented reality heads-up display. In addition to display technologies, DigiLens supplies light engines and hardware development kits, such as Insight30, which assist users in evaluating and developing wearable devices. Founded in 1997 and based in Sunnyvale, California, DigiLens has positioned itself as a leader in holographic waveguide technology, enabling various industries, including automotive, enterprise, consumer, avionics, and military, to leverage XR capabilities.

Tetra Therapeutics Inc. is a clinical-stage biotechnology company focused on developing pharmaceutical drugs that target phosphodiesterase (PDE) sub-type inhibitors for various neurological and non-neurological disorders. The company is known for its lead product, BPN14770, which aims to enhance brain synaptic function through the PKA-CREB pathway, addressing significant conditions such as Alzheimer's disease, schizophrenia, and developmental disabilities. Tetra Therapeutics also works on therapeutic solutions for individuals affected by traumatic brain injury and other psychiatric and neurodevelopmental disorders. Founded in 2011 and based in Grand Rapids, Michigan, the company was previously known as Tetra Discovery Partners, changing its name in August 2019. Tetra Therapeutics has established a strategic collaboration with Shionogi & Co., Ltd., and operates as a subsidiary of the same entity.

Podium Data, Inc. develops data management software solutions aimed at enhancing how businesses manage and utilize their data. Founded in 2014 and based in Lowell, Massachusetts, the company offers a platform that facilitates source parsing, conversion, validation, data profiling, metadata management, integration, encryption, and transformation. This platform is designed to transform the traditional data supply chain into a self-service marketplace, allowing clients to easily access and understand their enterprise data, regardless of its location. By leveraging big data technologies, Podium Data accelerates the time it takes for organizations to derive insights and make data-driven decisions, ultimately delivering immediate business impact and enabling analytics-ready data for users across various business functions. As of July 2018, Podium Data operates as a subsidiary of Qlik Technologies, Inc.

3Scan, Inc. specializes in developing advanced microscopy tools and software for automated tissue sectioning and imaging, primarily aimed at enhancing large-scale sample analysis and 3D visualizations. Founded in 2010 and based in San Francisco, California, the company focuses on addressing diseases that manifest at the tissue level, including cancer, heart disease, and neurodegenerative disorders. By integrating automation, machine learning, and computer vision, 3Scan's technology enables researchers and medical professionals to achieve greater throughput, improved quantification, and extensive image analysis compared to traditional histopathology methods. This data-driven approach aims to deepen the understanding of tissue biology, facilitating the discovery of new diagnostics and therapeutics. 3Scan was acquired by Transcriptic, Inc. in 2019.

Zebra Medical Vision Ltd. is a company that develops an imaging analytics platform aimed at enhancing patient care in healthcare institutions. Founded in 2014 and based in Shefayim, Israel, the platform utilizes advanced learning and computer vision algorithms to assist clinicians in identifying patients at risk of various diseases. This technology supports healthcare providers in implementing effective risk management and preventative care strategies. Zebra Medical Vision also supplies tools and datasets for machine-learning researchers, facilitating the rapid development of decision support tools and diagnostic solutions. The company has established strategic partnerships with organizations such as USARAD Holdings and TELUS Ventures, and has secured a total of $52 million in funding from notable investors, including Khosla Ventures and Nvidia. Its AI-driven products are FDA cleared and are utilized in hospitals across multiple regions, including the U.S., Europe, Australia, India, and Latin America, positioning Zebra Medical Vision as a leader in the field of medical imaging and analytics.

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Founded in December 2014 by award-winning protein folding expert, Susan Lindquist, and renowned biotech industry leader, Tony Coles, Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and addressing neurodegenerative diseases. The company's lead candidate, ATH-1017, is a small hepatocyte growth factor/MET activator designed to penetrate the blood-brain barrier and is currently undergoing various clinical trials for the treatment of Alzheimer's and Parkinson's diseases. Additionally, Athira is advancing other candidates, including ATH-1019, which is in preclinical development for depression, and ATH-1018, aimed at treating peripheral neuropathy. Founded in 2011 and originally named M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its commitment to innovative therapies that positively impact individuals affected by brain disorders.

Modsy is a home design service founded in 2015 and based in San Francisco, California. The company utilizes advanced 3D graphics and computer vision technology to create virtual interior environments, allowing customers to visualize furniture and décor in their own spaces before making purchases. Modsy caters to new homeowners, renters, and remodelers by offering personalized design guidance and plans tailored to individual preferences. Its platform not only showcases inspirational designs but also provides practical recommendations for room layouts and furnishings. Additionally, Modsy features a shoppable marketplace where customers can directly purchase the items featured in their designs, streamlining the home renovation process and reducing uncertainty for users.

Quince Therapeutics is a preclinical stage biopharmaceutical company dedicated to developing innovative precision therapeutics for debilitating and rare diseases. The company has created a unique bone-targeting drug platform that enables the precise delivery of small molecules, peptides, or large molecules directly to the site of bone fractures and diseases. This targeted approach aims to enhance healing rates while minimizing off-target safety concerns often associated with non-targeted therapies. Quince Therapeutics focuses on addressing impairments related to strength, functionality, debilitating pain, and other serious health challenges.

Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, specializing in the design and development of hearing aids for individuals with hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, along with online hearing screenings and virtual support services to eliminate the need for in-person visits. The company's innovative approach aims to address common barriers to hearing aid adoption, such as social stigma, accessibility, and cost, thereby enhancing the quality of life for its users. Eargo sells its products directly to consumers through online platforms, positioning itself as a modern alternative to traditional hearing aid solutions.

PharmatrophiX, Inc. is a biopharmaceutical company focused on developing disease-modifying small molecule drugs aimed at treating neurodegenerative disorders. Founded in 2005 and based in Menlo Park, California, the company utilizes its proprietary technology to enhance neurotrophin receptor signaling, which is essential for neuron health and survival. PharmatrophiX is known for its modified compound LM11A-31, which effectively penetrates the blood-brain barrier, making it a promising candidate for treating brain disorders. The company’s drug development efforts are geared towards halting neurodegenerative signaling while promoting regenerative processes, thereby offering potential therapeutic options for conditions such as Alzheimer's disease.